Remote Patient Care of Patients with Heart Failure A Focused Review on the HearLogic-System

Heart failure (HF) represents a growing clinical and socioeconomic burden worldwide, placing increasing pressure on healthcare systems in both high- and low-resource settings. Remote patient care (RPC), encompassing telemonitoring and other digitally enabled strategies, has emerged as a promising adjunct to conventional follow-up by enabling continuous physiological assessment and early detection of clinical deterioration. Such proactive surveillance facilitates timely therapeutic adjustments and may improve patient outcomes. A broad range of monitoring approaches is currently available or under development, including patient-directed home measurements, wearable technologies, and sensor-based solutions integrated into therapeutic cardiac implantable electronic devices (CIEDs). Among these, the HeartLogicTM multisensory algorithm offers a pragmatic and scalable solution, leveraging data from existing CIEDs without the need for additional procedures. It is a multiparametric, implant-based algorithm that detects early signs of HF decompensation by integrating sensor data, including heart sounds, intrathoracic impedance, respiratory rate, heart rate, and patient activity. Growing evidence supports its clinical utility. DANLOGIC-HF is the first randomized controlled trial designed to provide robust outcome data on whether HeartLogicTM-guided management reduces HF-related events. In this article the current evidence for HeartLogic™, as well as ongoing and planned clinical trials, with particular emphasis on the pragmatic randomized controlled trial DANLOGIC-HF.